0000000000480478

AUTHOR

G. Cavazzini

Evidence of magmatic activity related to Middle Jurassic and Lower Cretaceous rifting from northeastern Brazil (Ceará-Mirim): K/Ar age, palaeomagnetism, petrology and Sr/1bNd isotope characteristics

The Mesozoic magmatic activity in the easternmost part of NE Brazil (Ceara-Mirim) is mainly represented by two-pyroxene tholeiitic dykes; only few dykes have alkaline character. K/Ar ages and palaeomagnetism data indicate that Ceara-Mirim dykes are of Middle Jurassic (175-160 Ma) and Early Cretaceous (140-130 Ma) age. Both Middle Jurassic and Lower Cretaceous dykes have high incompatible-element concentrations and TiO2 with the lower contents generally confined to the Middle Jurassic dykes; rare tholeiitic dykes low in TiO2 and incompatible elements are present. Sr/1bNd isotopic and other chemical data do not support appreciable crustal contamination and in a 87Sr86Sr vs. 143Nd144Nd diagram…

research product

Lower Cretaceous tholeiitic dyke swarms from the Ponta Grossa Arch (southeast Brazil): Petrology, Sr-Nd isotopes and genetic relationships with the Paraná flood volcanics

The Lower Cretaceous dykes of the Ponta Grossa Arch, the most important dyke swarms in Brazil, are associated with the flood basalts and rare acid flows of the northern Parana basin. The Ponta Grossa (PG) dykes are formed by two-pyroxene tholeiites and rare acid rocks. The basaltic dykes may be distinguished into two main groups: a dominant, high-TiO2 (> 2 wt.%; HTi) group and a subordinate, low-TiO2 (< 2 wt.%; LTi) group, characterized, for similar MgO content, by high and low incompatible-element contents, respectively. Most PG dykes do not show chemical and isotope evidence supporting important crustal contamination. PG dykes with (87Sr86Sr)0 < 0.7060 plot in the mantle array (ϵSr ≈ + 17…

research product

Tholeiitic dyke swarm from the Ponta Grossa Arch and genetic relationships to the Paraná flood volcanics (Brazil)

research product

Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

research product